Market & Payment: Who Pays and How

1. Target Markets

Ranked by feasibility, clarity of buyer, and speed to first dollar.

1A. Opioid Overdose Prevention (Beachhead)

The numbers first. Opioid overdoses killed 54,045 Americans in 2024, down from 79,358 in 2023 (CDC NCHS, May 2025). Provisional data for 2025 show continued decline to roughly 70,000 total drug overdose deaths. The crisis is shrinking but not solved. Illicit opioids cost the U.S. an estimated $2.7 trillion in 2023 alone, equivalent to 9.7% of GDP (White House ONDCP, March 2025). Per-incident healthcare costs range from $504 for treat-and-release to $20,500 for ICU admission (Premier Inc.). The cost per fatal overdose, including lost productivity and statistical life value, reaches $11.5 million.

This is the beachhead because the buyer is obvious and funded.

Buyers: State harm reduction programs. SAMHSA-funded distribution networks. MAT clinics. Correctional systems releasing opioid-dependent inmates. The VA system. Each has budget authority, purchasing infrastructure, and political incentive.

Why first: Naloxone went OTC in 2023. Federal harm reduction funding, while under political pressure, allocated $58 million to first responder training programs in the current congressional cycle. The FR-CARA grant program funds naloxone distribution directly. Opioid settlement funds — over $50 billion nationally — are flowing to states now and need deployment targets. SmartShot's autonomous naloxone delivery fits within existing procurement categories.

The gap SmartShot fills: Naloxone works only if someone is present to administer it. A wearable that detects respiratory depression and delivers naloxone without bystander intervention addresses the majority of fatal overdoses, which occur when the user is alone.

1B. Anaphylaxis Management

The global epinephrine market reached $3.30 billion in 2025 and is projected to hit $6.87 billion by 2034 (Precedence Research). Auto-injectors account for 78% of that market. Approximately 225 Americans die from anaphylaxis annually.

The incumbent is broken. EpiPen retails at $550-$814 for a two-pack without insurance. With insurance, copays range from $5 to $200 depending on plan design. Several states have capped out-of-pocket costs: New York at $100, New Jersey at $25 per 30-day supply. A federal bill (the EPIPEN Act) would cap copays at $60 per two-pack but has not passed.

The deeper problem: EpiPen requires the patient to be conscious, oriented, and physically capable of self-injection. Children with severe allergies depend on a nearby adult. SmartShot is designed to remove the consciousness requirement.

Buyer: Prescribed through allergists. Paid through commercial insurance, Medicaid, or out-of-pocket. The reimbursement pathway mirrors existing epinephrine auto-injector coverage. Parents of allergic children represent the most motivated consumer segment in emergency medicine.

Competition: Mylan/Viatris (EpiPen), Kaleo (Auvi-Q), generic epinephrine auto-injectors. All require conscious manual activation.

1C. Cardiac Emergency Intervention

No competing auto-delivery solution exists in this category. Post-MI patients, patients with documented arrhythmia risk, and rural populations with extended EMS response times represent the addressable market.

Buyer: Prescribed through cardiologists. Covered under durable medical equipment (DME) benefit or pharmacy benefit depending on classification. The device-plus-drug model mirrors insulin pump reimbursement, where the device is billed as DME and consumables are billed separately.

Market sizing requires clinical trial data that does not yet exist. This is a Phase 2 market: entered after regulatory clearance in opioid or anaphylaxis indication establishes the platform.

1D. Institutional Markets

These are distinctive because the buyer and the patient are different entities.

Correctional facilities. U.S. correctional healthcare spending reached $9 billion in 2022. Courts increasingly mandate medication-assisted treatment for incarcerated populations with substance use disorders. SmartShot addresses compliance monitoring and autonomous delivery in a setting where staffing ratios make manual administration inconsistent. The buyer is the state department of corrections or the contracted healthcare provider (e.g., Corizon, YesCare).

Elderly care facilities. Medication errors affect 27% of nursing home residents. The elderly account for 35% of prescription medication use and 50% of medication errors despite being 12% of the population. Medication error-related adverse events add an average of 4.6 hospital days and $4,585 per incident. Total U.S. cost of medication administration errors exceeds $40 billion annually. SmartShot removes the human error variable from time-critical medication delivery.

Military and government. Field operatives, remote deployment, and environments where trained medical personnel are not available. This is a sole-source procurement opportunity through DoD and VA channels. Specific market sizing is classified or unavailable.

2. Reimbursement Strategy

SmartShot sits at the intersection of three existing reimbursement categories. None fits perfectly.

Existing CPT Codes That Partially Apply

Remote Patient Monitoring (RPM):

• 99453: Initial setup and patient education. Medicare reimburses $19.73 (2025).
• 99454: Device supply with daily recording, per 30 days. Medicare reimburses $43.02. Requires 16 days of data transmission per 30-day period.
• 99457: RPM treatment management, first 20 minutes. Medicare reimburses approximately $50.
• 99458: Each additional 20 minutes. Medicare reimburses approximately $42.

Medication Administration:

• 96372: Therapeutic/prophylactic/diagnostic injection, subcutaneous or intramuscular. Medicare reimburses $12.60-$18.00 depending on locality and facility status.

SmartShot's monitoring function maps to 99453/99454. The injection function maps to 96372. Neither code contemplates a device that does both autonomously.

The Gap

No CPT code exists for sensor-triggered autonomous injection. The closest analogy is the insulin pump, which is classified as DME (HCPCS E0784) with separate billing for insulin (J1817) and supplies (A4230). But insulin pumps deliver scheduled doses with manual override. SmartShot delivers emergency doses triggered by physiological detection. This is a new category.

Pathway to New Codes

Step 1: Category III code application through the AMA CPT Editorial Panel. Category III codes are temporary alphanumeric codes for emerging technology. The panel meets semi-annually with publication in January and July. Application requires evidence of clinical use and frequency data. Timeline from application to code publication: 6-18 months.

Step 2: Category I code conversion. Requires demonstrated widespread clinical use and published outcomes data. Typical timeline: 2-5 years after Category III issuance.

Step 3: RUC (Relative Value Scale Update Committee) valuation. Determines the relative value units that set Medicare payment rates. This process runs parallel to Category I conversion.

CMS Coverage Pathway

Two routes exist:

Local Coverage Determination (LCD): Issued by Medicare Administrative Contractors (MACs). Each MAC covers a geographic region. LCDs can be established within 365 days of proposal. This is the faster path and allows regional market entry while pursuing national coverage.

National Coverage Determination (NCD): Issued by CMS centrally. Takes 9-12 months from tracking sheet to final decision. Provides uniform national coverage. The new RAPID pathway, announced jointly by CMS and FDA in 2026, could reduce this to as little as two months for breakthrough devices.

Recommended approach: Pursue LCD in 2-3 favorable MAC regions simultaneously while preparing NCD application. Use LCD coverage data to support the NCD submission.

3. Payment Models

Device Sale + Subscription (Primary Model)

Hardware: One-time device purchase. Comparable reference points: insulin pumps at $5,000-$8,574, with most patients paying $0-$300/month after insurance. SmartShot's target price point should fall within this range to fit existing DME reimbursement infrastructure.

Monitoring service: Monthly subscription covering 24/7 sensor data processing, alert management, and clinical oversight. Billable under RPM codes 99453/99454/99457/99458. Estimated monthly revenue per patient: $50-$95 from RPM codes alone.

Drug cartridge refills: Recurring pharmaceutical revenue. Priced based on drug cost plus delivery system markup. Frequency depends on indication: naloxone cartridges may require annual replacement; epinephrine cartridges may follow similar shelf-life constraints to current auto-injectors (12-18 months).

Value-Based Contracts

Payers have appetite for outcome-linked pricing. Relevant metrics:

• Reduction in ER visits for enrolled patients vs. matched controls
• Reduction in overdose deaths (opioid indication)
• Reduction in anaphylaxis hospitalizations
• Reduction in medication error-related adverse events (institutional)

Structure: Base device fee plus bonus payments tied to demonstrated outcome improvement. Risk-sharing arrangement where SmartShot refunds a portion of fees if outcome targets are not met. This model requires 12-24 months of claims data to establish baselines.

HSA/FSA Eligibility

SmartShot qualifies as a medical device under IRS guidelines. Both the device and the monitoring subscription should be HSA/FSA eligible. This matters for the anaphylaxis market, where families with allergic children are accustomed to paying out-of-pocket for EpiPen.

Medicaid/Medicare Coverage

Medicare: DME benefit covers the device. Part B covers monitoring services under RPM codes. Part D may cover the drug cartridge depending on classification. Requires DMEPOS supplier enrollment and competitive bidding compliance.

Medicaid: Coverage varies by state. Medicaid expansion states offer broader device coverage. The opioid indication benefits from enhanced federal matching rates for SUD treatment services in many states.

Commercial Insurance

Coverage Evidence Development (CED) plan needed. This means demonstrating clinical utility through structured data collection during early market access. Commercial payers will require:

• Published clinical trial results (at minimum, pilot data)
• Health economic modeling showing cost offset
• Comparison to standard of care outcomes
• Endorsement from relevant medical societies

Timeline: 18-36 months from first commercial payer engagement to formulary/coverage inclusion.

4. Unit Economics Framework

These are estimates. They will be wrong. They exist to frame the business model, not to predict margin.

Device Hardware

Comparable wearable medical devices suggest a bill-of-materials (BOM) cost of $400-$800 for the sensor array, microprocessor, injection mechanism, and housing. Manufacturing at scale (10,000+ units) could reduce BOM to $250-$500. Retail price target: $3,000-$6,000, consistent with DME reimbursement norms.

Monthly Monitoring Service

Cloud infrastructure and data processing: $5-$10/patient/month at scale.
Clinical oversight staffing: $15-$25/patient/month (shared across patient panel).
Total cost of service delivery: $20-$35/patient/month.
Billable revenue (RPM codes): $50-$95/patient/month.
Gross margin on monitoring: 50-65%.

Drug Cartridge

Drug acquisition cost varies by indication:

• Naloxone: $20-$40 per dose (generic pricing)
• Epinephrine: $10-$30 per dose (generic pricing)

Cartridge packaging and sterility maintenance: $15-$25 per unit.
Replacement frequency: Annual (minimum) or after deployment.
Target cartridge price: $75-$150, yielding 40-60% gross margin.

Break-Even Framework

Per-patient annual revenue (device amortized over 3 years):

• Device: $1,000-$2,000/year (amortized)
• Monitoring: $600-$1,140/year
• Cartridge: $75-$150/year
• Total: $1,675-$3,290/year per patient

Per-patient annual cost:

• Device (amortized BOM + warranty): $150-$250/year
• Monitoring delivery: $240-$420/year
• Cartridge COGS: $35-$65/year
• Customer acquisition and support: $200-$400/year
• Total: $625-$1,135/year per patient

Implied gross margin per patient: $1,050-$2,155/year (63-65%).

Break-even patient count (assuming $2M annual fixed costs for a lean startup): 950-1,900 patients. This is achievable within 18-24 months of market entry in the opioid indication alone, given the scale of harm reduction programs.

These numbers need pressure-testing against real BOM quotes, actual RPM billing yields, and payer contract negotiations. They are directional, not precise.

5. Competitive Landscape

No Direct Competitor Exists

No company currently markets a wearable device that autonomously detects a physiological crisis and delivers injectable medication without user activation. This category does not exist yet.

Adjacent Competitors

Epinephrine auto-injectors: Mylan/Viatris (EpiPen), Kaleo (Auvi-Q), various generics. All require conscious manual activation. Market share concentrated in EpiPen despite pricing backlash. These are the displacement targets in the anaphylaxis indication.

Insulin pumps: Insulet (Omnipod), Medtronic (MiniMed 780G), Tandem (t:slim X2). Global market valued at $4.31 billion in 2024, projected to reach $7.27 billion by 2030. These represent the closest technical analogy — wearable devices that deliver medication based on sensor data — but they deliver scheduled doses, not emergency interventions. Insulin pumps validate the sensor-to-injection pipeline and the DME reimbursement model.

RPM platforms: BioTelemetry (now Philips), various telehealth monitoring companies. These handle the data side but not the intervention side. SmartShot's monitoring function competes with RPM platforms; its injection function has no RPM parallel.

What Happens If Apple, Abbott, or Medtronic Builds This

This is the right question. The honest answer: any of them could.

Apple has the sensor expertise and consumer hardware manufacturing at scale. But Apple has never sought FDA clearance for a drug-delivery device, and their regulatory posture is cautious. Watch health features took years to clear. Adding autonomous injection would represent a category shift Apple has shown no appetite for.

Abbott has the biosensor platform (FreeStyle Libre) and the regulatory experience. Abbott is the most likely acquirer if SmartShot proves the category. Abbott is less likely to build from scratch because their culture is incremental improvement of existing product lines, not category creation.

Medtronic has the closest technical capabilities: they already build sensor-driven injection systems (insulin pumps). Medtronic's challenge is organizational. Their insulin pump division is focused on the diabetes market. Building a multi-indication autonomous injection platform would require a new business unit, new regulatory submissions, and new commercial infrastructure. Medtronic is more likely to acquire or license than to build.

The window exists because large medtech companies do not create new categories. They acquire companies that have.

SmartShot's Defensible Position

Category naming: Reactive Medical Device (RMD) is SmartShot's term. If the category adopts this language, SmartShot owns the vocabulary.

Regulatory pathway research: The work documented in SmartShot Documents 1-4 — De Novo classification strategy, predicate device analysis, clinical trial design — represents 12-18 months of regulatory intelligence that a competitor would need to replicate.

Beachhead selection: The opioid overdose indication is not where a Medtronic or Abbott would start. It is low-margin, high-regulatory-burden, and socially complex. It is exactly where a startup should start because it has political tailwinds, public funding, and no incumbent.

First-mover advantage in reimbursement: The company that secures the first Category III CPT code for autonomous injection defines the billing infrastructure for every competitor that follows.